Why the Paragon Care share price is rocketing 83% today

The Paragon Care Ltd (ASX: PGC) share price is a standout performer on the market today as investors react to a business update.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paragon Care Ltd (ASX: PGC) share price is a standout performer on the market today as investors react to a business update.

At the time of writing, Paragon Care shares have rocketed 83.33% to 22 cents apiece.

Paragon Care is a provider of medical equipment, devices and consumables for the Australian and New Zealand healthcare market.

The company also offers equipment repair, maintenance and total equipment management through its service and technology division.

Over the years, the primary way Paragon Care has grown its business has been through acquisitions. As such, the company has a many number of brands under its banner, including Insight Surgical, REM Systems, MediTron, and Immulab.

asx share price growth represented by rocket flying up increasing bar chart.

Image source: Getty Images

Why is the Paragon Care share price spiking?

This afternoon, Paragon provided an update regarding the impact of COVID-19 on its business.

In prior trading updates, Paragon noted demand for its products and services were being affected by restrictions and the cancellation of non-essential elective surgery.

As such, Paragon's revenue in April 2020 tracked at 30% less than the prior year, allowing the company to be eligible for JobKeeper payments.

When Paragon disclosed these developments to the market in late April, it expected the significantly lower revenues to continue throughout the remainder of the June 2020 quarter.

However, the company announced today it has seen a "solid" improvement in its May and June revenues. Paragon attributed this to a higher than expected level of elective surgery cases due to recent favourable policy changes by the Federal Government.

As a result, the company is expecting its FY20 revenues to exceed $220 million. For context, Paragon delivered full-year revenues of $236 million in FY19.

Other developments

According to today's release, Paragon has made "significant progress" towards its previously announced strategy of delivering a more efficient cost structure. 

To date, the company has achieved more than $4 million of permanent annualised cost savings. It expects this amount to double over the next financial year.

Additionally, Paragon advised that its rationalisation of 14 individual businesses into four main pillar businesses is "well advanced". This rationalisation has seen the company integrate its businesses into the four pillars of devices, diagnostics, services, and capital & consumables.

Paragon said it will provide more details of this restructure, along with the associated costs, when it reports its full-year FY20 results in late August 2020.

Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A cool white-bearded man holds his hand up signalling you should halt.
Healthcare Shares

ASX 300 cannabis stock Incannex suspended ahead of 'material update'

The Incannex share price is frozen at 14 cents for now.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords stock is rocketing 27% on a new FDA approval

Rett Syndrome has finally got an approved treatment.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Buy these excellent ASX 200 healthcare shares: Goldman Sachs

Goldman has spoken very positively about these healthcare shares this week.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Guess which ASX biotech stock just rocketed 29% on big FDA news

The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares while they're under $300?

Can investors make a healthy return with this biotech?

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Mesoblast share price rockets 23% on FDA news

Mesoblast has received some good news for the US FDA this morning.

Read more »

A young woman wearing a blue blouse with white polkadots holds her phone up with an intrigued and happy look on her face as she reads some news.
Healthcare Shares

Owners of this ASX 200 share are soon going to receive a bigger dividend

Investors in this healthcare company are about to get a healthy cash boost.

Read more »

an older couple look happy as they sit at a laptop computer in their home.
Healthcare Shares

Hoping to collect the latest CSL dividend? Here's how

The next CSL dividend is fast approaching.

Read more »